Liraglutide Injection, Solution
Product Images NDC 81607-018

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 81607-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Orbicular Pharmaceutical Technologies Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 01)

Illustration showing the amino acid sequence of liraglutide with a C-16 fatty acid (palmitoyl) attached to a glutamic acid residue. The sequence is presented as individual amino acids arranged in a linear chain with labeled modifications.*

FDA Label Image

Figure 2 (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 02)

A line chart comparing ISR (pmol/kg/min) versus plasma glucose (mg/dL) for Liraglutide Injection and Placebo. It shows data points for both treatments, with Liraglutide Injection represented by dark diamond markers trending higher ISR values across glucose levels from about 90 to 220 mg/dL, while Placebo is shown with gray triangle markers at lower ISR values over the same glucose range.*

FDA Label Image

Figure 3 (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 03)

This line graph compares mean HbA1c (%) over 52 weeks for Glimepiride, Liraglutide Injection 1.2 mg, and Liraglutide Injection 1.8 mg. It shows HbA1c levels decreasing over time with Liraglutide doses generally resulting in lower levels than Glimepiride. Statistical significance markers are noted for differences between Liraglutide doses and Glimepiride.*

FDA Label Image

Figure 4 (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 04)

Line graph comparing mean HbA1c (%) over 26 weeks for Liraglutide Injection 1.2 mg, Liraglutide Injection 1.8 mg, and Sitagliptin 100 mg. Both Liraglutide doses show greater HbA1c reduction than Sitagliptin, with significance noted (p<0.0001). Y-axis measures mean HbA1c, x-axis shows time in weeks.*

FDA Label Image

Figure 5 (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 05)

A Kaplan-Meier plot comparing the percentage of patients with an event over time (months) between two groups: Placebo and Liraglutide Injection. The graph shows that over approximately 54 months, the Liraglutide Injection group consistently experienced fewer events than the Placebo group. A hazard ratio (HR) of 0.87 with a 95% confidence interval [0.78; 0.97] is indicated. Below the graph is a table showing patients at risk at various time points for both groups.*

FDA Label Image

Ifu Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 06)

Illustration diagram of the Liraglutide injection pen showing labeled parts including pen cap, rubber stopper, cartridge tip, cartridge scale, cartridge, dose display, pointer, dose selector, dose button, and flow check symbol. Also shown are needle components: outer needle cap, inner needle cap, needle, and protective tab, with a support phone number for pen usage issues.*

FDA Label Image

Carton3s (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 07)

The packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) solution for subcutaneous injection shows a carton designed to hold 3 prefilled pens. The label includes dosing information, storage instructions to refrigerate and not freeze, and manufacturer details for Orbicular Pharmaceutical Technologies Private Limited. It warns that the product is for single-patient use only and pen needles are not included.*

FDA Label Image

Carton2s (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 08)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) by Orbicular Pharmaceutical Technologies Private Limited. The label shows a blue pen injector with a dosage of 6 mg/mL, packaged as 2 pens per carton. It includes instructions for single-patient use, storage at or below 30°C, and that pen needles are not included.*

FDA Label Image

Label (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 09)

Label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) prefilled pen, subcutaneous solution. The label includes dosage details, storage instructions, single patient use warning, barcode, and manufacturing information by Orbicular Pharmaceutical Technologies Private Limited, Hyderabad, India.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 10)

An instructional diagram depicting a close-up view of a medication pen injector with a needle being removed. The image shows a hand pulling a protective needle cap straight off the pen, illustrating a step in preparing the Liraglutide 6 mg/mL subcutaneous injection for use.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 11)

An instructional illustration showing a hand pulling back the cap of a liraglutide injection pen, indicating preparation for subcutaneous administration. The image focuses on the first step in using the injection device for liraglutide 6 mg/mL solution.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 12)

An instructional diagram depicting a hand holding a pen-style injector with a finger pressing the plunger. The image shows a blue arrow indicating the direction of pressing the injector for subcutaneous injection.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 13)

An instructional diagram showing a hand pulling the cap off a pen injector device before use, indicated by an arrow pointing away from the pen. The image is related to the preparation or administration of a subcutaneous injection.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 14)

An instructional illustration showing a person adjusting the dosage dial on a Liraglutide injection device. The image highlights dosage selections of 0.6 mg, 1.2 mg, and 1.8 mg, with 0.6 mg currently selected, demonstrating dose selection steps for the subcutaneous injection solution.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 15)

An illustration diagram showing preferred subcutaneous injection sites for liraglutide injection solution. Highlighted areas for injection include the upper arms, stomach, and thigh of a simplified human figure.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 16)

An instructional illustration showing a hand adjusting a dial or cap on a Liraglutide injection pen device. The image highlights setting the dosage to 0 mg, with an arrow indicating the adjustment direction, emphasizing dose preparation for subcutaneous injection.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 17)

An instructional illustration showing a hand holding a liraglutide injection pen against the arm with a downward arrow indicating injection. A timer set to 6 is displayed below, suggesting a wait or count of six seconds post-injection.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 18)

An instructional diagram showing the tip of a pen injection device with a needle pointing downward. A large blue arrow above the device points upward, possibly indicating the correct injection direction or an action to perform with the pen for subcutaneous use.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 19)

An instructional diagram showing the correct way to attach a needle to a pen injector for subcutaneous injection. The image depicts a pen injector on the right and a needle on the left, with an arrow indicating the needle should be pushed onto the pen injector.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 2)

An instructional illustration showing a close-up of a person holding a blue injection pen, with a thumb pressing the plunger to administer a subcutaneous injection. The diagram highlights the act of pushing the injection pen against the skin, indicated by a blue arrow pointing downward.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 20)

An instructional illustration showing a close-up of a hand holding a liraglutide injection pen. The image demonstrates the step of pulling off a blue pen cap by indicating an arrow pointing away from the pen tip, guiding the user to remove the cap before injection.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 3)

An instructional illustration showing a hand holding a syringe for subcutaneous injection and rotating the dial or plunger, presumably to set or adjust the dose of Liraglutide injection, solution 6 mg/mL.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 4)

An instructional illustration showing a hand holding a syringe with the needle pointing outward and an arrow indicating to pull or push the syringe in the direction away from the hand. The image is labeled with the letter 'C' in the top left corner, suggesting it is part of a multi-step process.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 5)

An instructional illustration showing a hand pulling off a protective cap from a prefilled syringe or pen injector, with a blue arrow indicating the direction of removal. This image likely demonstrates a step in preparing a liraglutide injection, solution for subcutaneous use.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 6)

LIRAGLUTIDE 6 mg/mL injection, solution for subcutaneous use, shown in a vial packaging. The label includes the proprietary and generic name, strength, dosage form, and the labeler Orbicular Pharmaceutical Technologies Private Limited. The image displays the vial with a white and blue label.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 7)

Instructional illustration showing a close-up of hands selecting a flow check symbol on a device, with a small inset highlighting the flow check symbol itself. The image is related to LIRAGLUTIDE injection, indicating proper preparation or verification steps for subcutaneous administration.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 8)

An instructional diagram showing a hand holding a prefilled injection pen for subcutaneous use, with a close-up on the needle cap removal step. The illustration highlights the preparation of the liraglutide injection pen before administration.*

FDA Label Image

Image (026b3564 4bf1 4f85 B7c7 Abd03c8d9c3d 152 9)

Illustration showing a hand holding a Liraglutide injection pen with the dosage dial set to 0 mg, demonstrating how to prepare the device for subcutaneous injection by pulling the pen upward.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.